BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Forecasted to Earn FY2025 Earnings of $1.98 Per Share

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of BioMarin Pharmaceutical in a report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $1.98 for the year, down from their previous estimate of $2.16. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $2.37 EPS.

Several other brokerages have also recently weighed in on BMRN. Piper Sandler dropped their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Royal Bank of Canada reiterated a “sector perform” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Robert W. Baird lowered their target price on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 30th. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $91.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 29th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.61.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $88.63 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12. The stock’s fifty day simple moving average is $87.61 and its two-hundred day simple moving average is $89.12. BioMarin Pharmaceutical has a 1-year low of $76.02 and a 1-year high of $99.56. The stock has a market cap of $16.73 billion, a PE ratio of 100.72, a price-to-earnings-growth ratio of 1.67 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The business had revenue of $646.21 million for the quarter, compared to analysts’ expectations of $639.53 million. During the same period last year, the business earned $0.11 EPS. The business’s revenue was up 20.2% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of BioMarin Pharmaceutical by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 18,050,062 shares of the biotechnology company’s stock worth $1,740,387,000 after purchasing an additional 348,852 shares during the last quarter. Capital Research Global Investors increased its position in shares of BioMarin Pharmaceutical by 79.0% in the fourth quarter. Capital Research Global Investors now owns 10,774,641 shares of the biotechnology company’s stock worth $1,038,907,000 after purchasing an additional 4,756,671 shares during the last quarter. Barclays PLC increased its position in shares of BioMarin Pharmaceutical by 31.6% in the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company’s stock worth $493,111,000 after purchasing an additional 1,336,886 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of BioMarin Pharmaceutical by 5.6% in the third quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company’s stock worth $456,906,000 after purchasing an additional 275,436 shares during the last quarter. Finally, Viking Global Investors LP increased its position in shares of BioMarin Pharmaceutical by 16.0% in the fourth quarter. Viking Global Investors LP now owns 4,889,454 shares of the biotechnology company’s stock worth $471,441,000 after purchasing an additional 673,998 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the completion of the transaction, the director now owns 474,994 shares of the company’s stock, valued at approximately $43,347,952.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the completion of the transaction, the director now owns 474,994 shares of the company’s stock, valued at approximately $43,347,952.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total value of $3,010,346.38. Following the transaction, the insider now directly owns 212,117 shares of the company’s stock, valued at approximately $18,068,126.06. The disclosure for this sale can be found here. Insiders sold 103,229 shares of company stock valued at $9,062,967 in the last quarter. 1.84% of the stock is currently owned by corporate insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.